Market Closed - Xetra 11:36:33 2024-03-04 am EST After market 03:59:56 pm
65.22 EUR -0.43% Intraday chart for MorphoSys AG 65.37 +0.23%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
INDEX-MONITOR: Morphosys and Vitesco likely to swap places in March DP
MORPHOSYS : UBS sticks Neutral ZD
Novartis' Midterm Sales Growth Prospects Limited as Patent Expirations Loom, Berenberg Says MT
INDEX-MONITOR: Morphosys and Vitesco to swap places in MDax and SDax in March DP
MORPHOSYS : UBS revises his opinion and turns to Neutral ZD
European Equities Traded in the US as American Depositary Receipts Slightly Lower in Wednesday Trading MT
MORPHOSYS : UBS remains its Buy rating ZD
Swiss Market Index Blinks Red Amid Renewed Rate Jitters MT
Global markets live: BP, Palantir, Infineon, Toyota, UBS... Our Logo
Novartis wants to swallow Morphosys - access to beacon of hope DP
Dpa-AFX Overview: COMPANIES from 06.02.2024 - 15:15 DP
Transcript : MorphoSys AG, Novartis AG - M&A Call
North American Morning Briefing : Rate Doubts Keep Pressure on Stocks; More Earnings in Focus DJ
MORPHOSYS : UBS reiterates its Buy rating ZD
European Midday Briefing : Stocks Higher But Gains Capped On Rate Doubts DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET DJ
MorphoSys Shares Jump After It Agrees to $2.9 Billion Takeover by Novartis DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET DJ
BP earnings, China stimulus lift European stocks at open RE
Morphosys share price approaches Novartis offer DP
Novartis: agreement on a friendly takeover bid for MorphoSys CF
News Highlights : Top Company News of the Day - Tuesday at 1 AM ET DJ
EMEA Morning Briefing : Stock Futures Track Higher as Investors Parse More Fedspeak DJ
Novartis Strikes EUR2.7 Billion Deal to Buy German Biopharmaceutical Group MorphoSys MT
News Highlights : Top Company News of the Day - Monday at 11 PM ET DJ
Chart MorphoSys AG
More charts
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
65.22 EUR
Average target price
50.38 EUR
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock MorphoSys AG - Xetra
  4. News MorphoSys AG
  5. European Equities Traded in the US as American Depositary Receipts Ease to Start Week
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.